PRESENTATION

Q2 2023 — Results presentation

Q2 2023PDF · 30 pages2.3 MB
1

-- 1 of 30 --

2nd Quarter 2023
Earnings Call
July 20, 2023

-- 2 of 30 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on
these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as
interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action,
including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in
behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the
health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely
basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health
Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual
Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in
Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
3

-- 3 of 30 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and
commercialize for a broad range of indications
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension 	UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 30 --

5
Agenda
CEO Remarks
Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
1
2
3
4
5
Joaquin Duato
Chairman of the Board and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Erik Haas
Worldwide Vice President,
Litigation
Jessica Moore
Vice President,
Investor Relations

-- 5 of 30 --

Joaquin Duato
Chairman of the Board and Chief
Executive Officer

-- 6 of 30 --



-- 7 of 30 --



-- 8 of 30 --

9
Pharmaceutical
• 	Regulatory:
– 	Janssen Marks First Approval Worldwide for AKEEGA (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration
Resistant Prostate Cancer with BRCA1/2 Mutations
– 	Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
– 	Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary
Arterial Hypertension (PAH)
– 	Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma
• 	Data Release:
– 	Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti-PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive
Bladder Cancer
– 	First Phase 3 TREMFYA (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis
– 	Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and
Pipeline in Hematologic Malignancies and Solid Tumors
– 	New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
– 	Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis 2
– 	Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with
Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer2
• 	Other
– 	Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
MedTech
• 	Data Release:
– 	New Data Published on Biosense Webster QDOT MICRO Catheter – the Latest Advancement in Focal RF Ablation for Treating AFib
Enterprise
– 	Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow
1 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com
2 Subsequent to the Quarter
Notable Announcements in the 2nd Quarter 1

-- 9 of 30 --

Jessica Moore
Vice President,
Investor Relations

-- 10 of 30 --

Regional Sales Results 	Q2 2023 	Q2 2022
% CHANGE
Reported 	Operational1
U.S. 	$13.4 	$12.2 	10.2% 	10.2%
Europe 	5.9 	6.1 	(3.1) 	(3.9)
Western Hemisphere
(ex U.S.) 1.7 	1.5 	11.5 	17.7
Asia-Pacific, Africa 	4.5 	4.2 	6.6 	12.5
International 	12.1 	11.8 	2.2 	4.7
Worldwide (WW) 	$25.5 	$24.0 	6.3% 	7.5%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
2nd Quarter 2023 Sales
Dollars in Billions
11

-- 11 of 30 --

$1.96 $1.80
$25.5 $24.0 	$5.1 $4.8
8.1%; 9.7% 1
Q2 2023 	Q2 2022
2nd Quarter 2023 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational % 1
12
Sales
Adjusted Earnings 2 Adjusted EPS2
6.3%; 7.5% 1
GAAP Earnings
6.9%
6.5%
Q2 2023 	Q2 2022
8.9%
Q2 2023	Q2 2023 	Q2 2022 	Q2 2022	Q2 2023 	Q2 2022
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
Note: Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
$2.80
$2.59
GAAP EPS
$7.4 $6.9

-- 12 of 30 --

Immunology
$4,496
Infectious Diseases
$1,121
Neuroscience
$1,793
Oncology
$4,398 	CVM/Other
$950
PH
$972
$13,731
3.1%, 3.8%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
Key Drivers of Operational Performance1
Immunology
• 	STELARA increase driven by market growth partially offset by unfavorable patient mix
and rebates
• 	Growth in TREMFYA due to share gains and market growth, partially offset by unfavorable
patient mix
• 	REMICADE decline due to biosimilar competition
Infectious Diseases 	• 	COVID-19 Vaccine revenue decline
Neuroscience
• 	SPRAVATO growth driven by ongoing launches in the U.S. and Europe
• 	Growth partially offset by declines from the paliperidone long-acting injectables, due to the
XEPLION loss of exclusivity in EU
Oncology
• 	DARZALEX increase driven by share gains in all regions and continued market growth
• 	Continued share gains and market growth in mCSPC, and increased penetration from
new launches for ERLEADA
• 	CARVYKTI increase driven by continued market share gains from ongoing launch
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA decline due to
global competitive pressure. Imbruvica maintains its market leadership position
Cardiovascular/
Metabolism/
Other (CVM/Other)
• 	XARELTO increase due to favorable patient mix and market growth, partially offset by
share loss
Pulmonary
Hypertension (PH)
• 	Increase driven by favorable patient mix, share gains, and market growth from UPTRAVI
and OPSUMIT
• 	Continued declines in Other Pulmonary Hypertension
Adjusted Operational Sales2: WW 3.9%, U.S. 9.2%, Int’l (2.2)%
Pharmaceutical Highlights – 2nd Quarter 2023
Reported: 	WW 3.1%, U.S. 9.2%, Int’l (4.0)%
Operational1: 	WW 3.8%, U.S. 9.2%, Int’l (2.5)%
(2.2)%, (2.0)%
15.3%, 16.5%
8.8%, 9.7%
(14.8)%, (16.6)% 	1.9%, 2.6%
Strong operational growth 1 of 6.2% excl. COVID-19 Vaccine driven by Oncology, Immunology, and PH
3.5%, 5.5%
13

-- 13 of 30 --

Key Drivers of Operational Performance1
Interventional
Solutions
• 	Electrophysiology: Double digit increase due to global procedure growth, new product performance
(QDOT & OCTARAY) and commercial execution, partially offset by impacts from volume-based
procurement in China (VBP impacts)
• 	Abiomed: Acquired December 22, 2022; strength from all commercialized regions and continued adoption
of Impella 5.5 and Impella RP
Orthopaedics
• 	Hips: Reflects global procedure growth and continued strength of the portfolio (primarily in the Anterior
approach), partially offset by supply challenges
• 	Trauma: Growth primarily driven by procedure recovery and adoption of recently launched products
(Advanced Nailing Systems, Cannulated Compression Headless Screws, CrossRoads Extremity, and VA
Clavicle) partially offset by VBP impacts
• 	Knees: Reflects global procedure recovery, benefits from launches in the ATTUNE portfolio (Cementless
& Medial Stabilized), and pull through related to the VELYS Robotic assisted solution, partially offset by
supply constraints
• 	Spine, Sports & Other: Primarily driven by procedure growth, positive uptake of new products (INHANCE
& SYMPHONY), and growth in VELYS digital solutions, partially offset by VBP impacts and continued
competitive pressures in Spine
• 	Spine: ~ +2% WW, ~ -1% U.S., ~ +5% OUS
Surgery
• 	Advanced:
• 	Endocutters: ~ +5% Growth primarily due to procedure recovery outside of the U.S. and uptake of
recently launched products (ECHELON 3000, GST reloads, and ECHELON+), partially offset by VBP
impacts, competitive pressures predominately in the U.S., and supply challenges
• 	Biosurgery: ~ +18% Increase driven by global procedure growth and strength of the portfolio
(SURGIFLO, SURGICEL Powder, and VISTASEAL)
• 	Energy: ~ +3% Driven by procedure recovery outside of the U.S. and strength of new products
(HD1000i), partially offset by VBP impacts and supply challenges
• 	General: Growth primarily due to procedure recovery outside of the U.S. coupled with technology
penetration and benefits from our differentiated Wound Closure portfolio (Barbed & PLUS Sutures)
Vision
• 	Contact Lenses/Other: Growth driven by continued strong performance of the ACUVUE OASYS 1-Day
family (including recent launches of OASYS MAX 1-day and OASYS Multifocal), and commercial
execution, partially offset by impacts from strategic portfolio decisions and supply challenges
• 	Surgical: Reflects cataract procedure growth and continued strength of recent innovation (TECNIS
EYHANCE), partially offset by softer Refractive and premium IOL markets
Adjusted Operational Sales 2: WW 9.9%, U.S. 6.5%, Int’l 13.0%
Orthopaedics
$2,265
Surgery
$2,594
Vision
$1,308
Interventional
Solutions
$1,620
$7,788
12.9%, 14.7%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Exceptional operational growth 1 fueled by innovation and strong commercial execution across all franchises
Reported: 	WW 12.9%, U.S. 14.6%, Int’l 11.3%
Operational1: 	WW 14.7%, U.S. 14.6%, Int’l 14.7%
54.4%, 56.9%
5.4%, 6.9%
5.0%, 5.7%
5.9%, 8.4%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
14
MedTech Highlights – 2nd Quarter 2023

-- 14 of 30 --

OTC
$1,659
Skin Health/Beauty
$1,148
Oral Care
$398
Baby Care
$360
Women's Health
$238
Wound Care/Other
$207
$4,011
5.4%, 7.7%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Consumer Health Highlights – 2nd Quarter 2023
Operational growth 1 primarily driven by OTC
Key Drivers of Operational Performance1
OTC • 	Growth driven by price actions, and strong TYLENOL and MOTRIN performance due
to increased global Cough/Cold/Flu incidences
Skin
Health/
Beauty
• 	Growth driven by price actions and strength in NEUTROGENA particularly in Sun,
driven by innovation and supply repositioning
Oral Care • 	Growth driven by price actions, partially offset by category deceleration in Asia and
suspension of personal care sales in Russia
Baby Care • 	Decline driven by competitive pressures in Asia, and suspension of personal care
sales in Russia
Women’s
Health
• 	Growth driven by price actions and continued strong growth in India, partially offset by
suspension of personal care sales in Russia
Wound
Care/Other • 	Growth driven by price actions and innovation
Adjusted Operational Sales2: WW 7.7%, U.S. 6.0%, Int’l 9.0%
Reported: 	WW 5.4%, U.S. 6.0%, Int’l 5.0%
Operational1: 	WW 7.7%, U.S. 6.0%, Int’l 9.0%
12.0%, 13.9%
3.4%, 10.0%
4.9%, 6.8%
(4.0)%, (0.2)%
0.9%, 2.7%
2.0%, 3.5%
15
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding

-- 15 of 30 --

2023 	2022 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$25,530 	100.0 	$24,020 	100.0 	6.3
Cost of products sold 	8,212 	32.2 	7,919 	33.0 	3.7
Gross Profit 	17,318 	67.8 	16,101 	67.0 	7.6
Selling, marketing and administrative expenses 	6,665 	26.1 	6,226 	25.9 	7.1
Research and development expense 	3,829 	15.0 	3,703 	15.4 	3.4
Interest (income) expense, net 	(23) 	(0.1) 	(26) 	(0.1)
Other (income) expense, net* 	(60) 	(0.2) 	273 	1.1
Restructuring 	145 	0.5 	85 	0.4
Earnings before provision for taxes on income 	6,762 	26.5 	5,840 	24.3 	15.8
Provision for taxes on income 	1,618 	6.4 	1,026 	4.3 	57.7
Net Earnings 	$5,144 	20.1 	$4,814 	20.0 	6.9
-
Net earnings per share (Diluted) 	$1.96 	$1.80 	8.9
Average shares outstanding (Diluted) 	2,625.7 	2,667.9
Effective tax rate 	23.9% 	17.6%
.
Adjusted earnings before provision for taxes and net earnings 1
Earnings before provision for taxes on income 	$8,824 	34.6 	$8,171 	34.0 	8.0
Net earnings 	$7,358 	28.8 	$6,912 	28.8 	6.5
Net earnings per share (Diluted) 	$2.80 	$2.59 	8.1
Effective tax rate 	16.6% 	15.4%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter. 	16
2 nd Quarter 2023
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 16 of 30 --

2023 	2022
Adjusted Income Before Tax by Segment1
2 nd Quarter 2023
17
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
Q2 2023 	Q2 2022
Pharmaceutical 	42.7% 	42.0%
MedTech 	28.6% 	26.5%
Consumer Health 	23.5% 	25.9%
Total 	34.6% 	34.0%
% to Sales
($0.2) 	($0.2)
$8.2B
$5.6
$1.8
$1.0
$8.8B
$5.9
$2.2
$0.9
2
1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 Estimated as of 7/20/2023

-- 17 of 30 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 18 of 30 --

19

-- 19 of 30 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions 	Q2 2023
Cash and Marketable
Securities $29
Debt 	($46)
Net Debt* 	($17)
Free Cash Flow1,2 ~$5.4.
Q2 2023:
$3.8B invested in R&D
$7.4B year-to-date
$3.1B in dividends paid
to shareholders;
$6.0B year-to-date
Note: values may have been rounded
* Includes approximately $7B of Kenvue Net Debt
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of July 20, 2023. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 Announced $5B share repurchase program on September 14, 2022 	20
Note: values may have been rounded
$2.5B in share repurchases year-to-date;
100% of the program completed 3

-- 20 of 30 --

21
2023 Guidance Summary
January Adjusted Operational EPS1 $10.50
Improved Performance Outlook 	0.05
April Adjusted Operational EPS1 $10.55
Collaboration and License Agreement
with Cellular Biomedicine Group (0.10)
Kenvue Non-Controlling Interest 	(0.08)
Improved Performance Outlook 	0.28
New July Adjusted Operational EPS1 $10.65
Improved performance outlook driving higher adjusted operational earnings
per share1 guidance
1 Non-GAAP measure; excludes the impact of translational currency; excludes intangible amortization expense and special items
Note: Adjusted Operational EPS figures reflect midpoint of issued guidance

-- 21 of 30 --

1 Non-GAAP measure; excludes acquisitions and divestitures 	5 Sales less: COGS, SM&A and R&D expenses
2 Non-GAAP measure; excludes the impact of translational currency 	6 Excludes COVID-19 Vaccine
3 Euro Average Rate: July 2023 = $1.09; Euro Spot Rate: July 2023 = $1.10 	7 Includes $200MM of non-controlling interest
4 Non-GAAP measure; excludes intangible amortization expense and special items 	Note: Percentages may be rounded 	22
2023 P&L Guidance
July 	April 	Comments
Adjusted Operational Sales1,2,6 	6.0% - 7.0% 	4.5% - 5.5% 	Increasing midpoint to 6.5%
Operational Sales 2,6 	$99.3B - $100.3B
7.0% - 8.0%
$97.9B - $98.9B
5.5% - 6.5% Increasing midpoint by $1.4B to 7.5%
Estimated Reported Sales 3,6 	$98.8B - $99.8B
6.5% - 7.5%
$97.9B - $98.9B
5.5% - 6.5%
Increasing midpoint by $0.9B to 7.0%
Incremental FX ($0.5B)
Adjusted Pre-Tax
Operating Margin4,5 	Slight Improvement 	Approximately flat Increasing primarily due to expense
management
Net Other Income 4 	$1.6 - $1.8 billion 7 	$1.9 - $2.1 billion Reducing to account for non-controlling
interest in Kenvue Inc.
Net Interest Expense / (Income) 	$150 - $250 million 	$250 - $350 million Reducing due to interest income on net
proceeds from Kenvue separation
Effective Tax Rate 4 	15.5% - 16.5% 	15.5% - 16.5% 	Maintaining
Adjusted EPS (Operational) 2,4 	$10.60 - $10.70
4.5% - 5.5%
$10.50 - $10.60
3.5% - 4.5%
Maintain range;
Increasing midpoint by $0.10
Adjusted EPS (Reported) 3,4 	$10.70 - $10.80
5.5% - 6.5%
$10.60 - $10.70
4.5% - 5.5%
Maintain range;
Increasing midpoint by $0.10
Raising top- and bottom-line guidance due to strong Q2 performance

-- 22 of 30 --

MedTech
• 	Anticipate normal seasonality and stable procedure volumes and staffing levels for the balance of the year
• 	Expect continued competitive performance, continued uptake of recently launched products, and improving supply
• 	Potential for accelerated back half headwinds from volume-based procurement and international sanctions
Pharmaceutical
• 	Continue to anticipate another year of above-market adjusted operational sales growth
• 	Expect slightly higher operational sales growth in the second half of the year compared to the first half
• 	Anticipate continued uptake of newly launched products
Consumer Health
• 	Lapping prior year price increases in the back half of the year
2023 Phasing Considerations
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Excludes COVID-19 Vaccine
2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded
3 Euro Average Rate: July 2023 = $1.09; Euro Spot Rate: July 2023 = $1.10
July 	April
Adjusted Operational Sales1,2,4 6.0% - 7.0% 	4.5% - 5.5%
Operational Sales2,4 $99.3B - $100.3B
7.0% - 8.0%
$97.9B - $98.9B
5.5% - 6.5%
Estimated Reported Sales3,4 $98.8B - $99.8B
6.5% - 7.5%
$97.9B - $98.9B
5.5% - 6.5%
23

-- 23 of 30 --

24
Driving Meaningful Value Creation
Pharmaceutical
Growth of existing assets
Upcoming pipeline advancements
Regulatory and clinical milestones
Continued uptake of newly
launched products
MedTech
Commercial execution
Upcoming pipeline advancements
Exposure to higher growth markets
Driving continued adoption of
recently launched products

-- 24 of 30 --

25
Additional
Q2 2023
Highlights

-- 25 of 30 --

Reminder:
Save the Date
Introducing Our
First Ever…
Enterprise
Business
Review
Focused on the New Johnson
& Johnson
Tuesday, December 5, 2023
New York Stock Exchange

-- 26 of 30 --

Erik Haas
Worldwide Vice President,
Litigation

-- 27 of 30 --

Q&A
Erik Haas
Worldwide Vice President,
Litigation
Chairman of the Board and
Chief Executive Officer
Joaquin Duato 	Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations

-- 28 of 30 --



-- 29 of 30 --



-- 30 of 30 --